However, GLP-1 receptor agonists had no significant effects on the occurrence of thyroid cancer (RR 1.30, 95% CI 0.86-1.97), hyperthyroidism (RR 1.19, 95% CI 0.61-2.35), hypothyroidism (RR 1.22, 95% CI 0.80-1.87), thyroiditis (RR 1.83, 95% CI 0.51-6.57), thyroid mass (RR 1.17, 95% CI 0.43-3.20), and goiter (RR 1.17, 95% CI 0.74-1.86)
There are also warnings about thyroid Ccell tumors in animal studies for some drugs, and clinician screening is important
Whilst these risks are generally mitigated where #GLP1s are provided as part of a multidisciplinary care approach, many patients are accessing them via online pharmacies
Manufactured by RPL Peptide, each batch is supported by quality control procedures including chromatographic and mass spectrometric verification to ensure identity and purity consistency for research applications
Frequently Asked Questions How much GHK-Cu should I inject daily